
 Insurance Dilemma: The Leqembi Debate Shaping Alzheimer’s Treatment Access
The introduction of the first drug approved to slow cognitive decline in Alzheimer’s patients, Leqembi, has ignited debates over insurance coverage. While Medicare has opted





